asta-7654 and Pain

asta-7654 has been researched along with Pain* in 1 studies

Trials

1 trial(s) available for asta-7654 and Pain

Article	Year
Phase I study of cyclohexylamine and lysine salt of mafosfamide. Cancer chemotherapy and pharmacology, 1986, Volume: 16, Issue:2 Mafosfamide is a new oxazaphosphorine that breaks down spontaneously into 4-hydroxy-cyclophosphamide. A phase I trial with cyclohexylamine and lysine salts of mafosfamide was carried out in 16 patients, using weekly IV perfusion. Dose-limiting toxicities were not hematological, but consisted in the development of severe pain along the vein during administration. A particular mucosal syndrome with sneezing and conjunctivitis was seen only after administration of the lysine salt. The dose of 700 mg/m2 per week represents the maximum tolerated dose with this weekly schedule. Topics: Adult; Aged; Blood Cell Count; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplasms; Pain	1986

Article

Year

Phase I study of cyclohexylamine and lysine salt of mafosfamide.

Cancer chemotherapy and pharmacology, 1986, Volume: 16, Issue:2

Mafosfamide is a new oxazaphosphorine that breaks down spontaneously into 4-hydroxy-cyclophosphamide. A phase I trial with cyclohexylamine and lysine salts of mafosfamide was carried out in 16 patients, using weekly IV perfusion. Dose-limiting toxicities were not hematological, but consisted in the development of severe pain along the vein during administration. A particular mucosal syndrome with sneezing and conjunctivitis was seen only after administration of the lysine salt. The dose of 700 mg/m2 per week represents the maximum tolerated dose with this weekly schedule.

Topics: Adult; Aged; Blood Cell Count; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplasms; Pain

1986